The Growing Case for Use of SGLT2i in Heart Failure: Additional Benefits of Empagliflozin in a HFpEF Rodent Model
JACC Basic Transl Sci
.
2019 Feb 25;4(1):38-40.
doi: 10.1016/j.jacbts.2019.01.003.
eCollection 2019 Feb.
Authors
Chae-Myeong Ha
1
,
Adam R Wende
1
Affiliation
1
Department of Pathology, Division of Molecular and Cellular Pathology, University of Alabama at Birmingham, Birmingham, Alabama.
PMID:
30847417
PMCID:
PMC6390674
DOI:
10.1016/j.jacbts.2019.01.003
No abstract available
Keywords:
HFpEF; SGLT2i; heart failure.
Publication types
Editorial
Grants and funding
P30 DK079626/DK/NIDDK NIH HHS/United States